The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

berlex.com

Stage

Acquired | Acquired

Total Raised

$13M

Valuation

$0000 

Revenue

$0000 

About Diatide

Diatide, Inc. was founded as a private radiodiagnostic company and in 1999 became Diatide Research Laboratories, a division of Berlex Laboratories focused on developing and making specialized medicines. Diatide was engaged in the imaging marketplace, engaged in peptide engineering, molecular biology and radiolabeling chemistry to develop disease-specific diagnostic and therapeutic agents.

Diatide Headquarter Location

Nine Delta Drive

Londonderry, New Hampshire, 03053,

United States

603-437-8970

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

You May Also Like

N
Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

G
Gold Standard Diagnostics

Gold Standard Diagnostics (GSD) provides diagnostic solutions that improve lab efficiency and minimize overall costs. Through an extensive product menu, automated instrument platforms, and outstanding customer service, GSD solves real laboratory problems. The result is a seamless laboratory experience achieved through an integrated approach.

L
LifeLineLab S.r.l.

Lifelinelab s.r.l. started its activities in April 2003, thanks to the commitment of three managers coming from the ex Diagnostic Division Manufacturing Plant of Alfa Wassermann S.P.A. First step has been to secure raw materials, and equipment for R&D and Manufacturing of products and services in the field of Human in Vitro Diagnostics. nnnnnFirst diagnostic reagents were manufactured, in this site, over 40 years ago, through the bravery and the enterprising spirit of Prof. Balducci ex Managing Director of Virology Laboratory of "Istituto Superiore di Sanitu00e0". First products were based on tissue colture technology included a line of complement fixation antigens. Since then, the company developed methods and products, covering almost all the fields of Human in Vitro Diagnostics, from Clinical Chemistry to Immunochemistry. The mostly developed sector has been that of Infectious Diseases with particular regard to Viral pathologies. Most products have been developed using biological raw materials derived from in house, in vivo or in vitro, productions. Nowadays the company aims to face and develop markets with consolidate and emerging technologies such as Microarrays using a chemistry patented and designed to covalently bind either Protein or Nucleic acids which aims to allow the development of extremely sophisticated analysis in the emerging applications of proteomics and genomics.

C
Cellatope Corporation

Cellatope is a cell analysis company that is developing research and diagnostic products and services in the field of autoimmune and inflammatory disease, with an initial focus on lupus and transplant medicine.

i
iMMCO Diagnostics

IMMCO Diagnostics provides high-quality diagnostic test kits and lab testing services worldwide for the screening of autoimmune disorders. IMMCO Diagnostics incorporates working on research, clinical laboratory expertise, and medical devices into an approach to autoimmune diagnostics.

P
PsychNostics

PsychNostics, LLC has developed a diagnostic blood test for Bipolar Disorder and ADHD. This propreitory test uses the Membrane Potential Ratio ( MPR ) as a diagnostic blood test marker for Bipolar Disorder (BPD) and Attention Deficit Hyper Active Disorder (ADHD). The test results have been published in peer reviewed scientific journals. Clinical psychiatrists have validated the reliability of this test through clinical trials. PsychNostics, LLC is currently engaged in the development of broader uses of this technology nationwide. Further research is underway to elucidate the biological pathway and the proteins involved so that they could be used as drug targets for developing more effective drugs for these illnesses. Efforts are being made to partner co-development and marketing arrangements with other companies to develop these technologies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.